【深圳商报讯】（记者 刘娥）近日，深圳华诺生物科技有限公司（以下简称"华诺生物"）宣布完成 A+轮融资，由国中资本领投，深产投跟投。本轮融资将主要用于基于自主研发的自愈合超分子技术平 台的产品管线扩充及核心产品的产能升级。 华诺生物创新性地将"自愈合超分子"技术用于可注射、可塑形的流体类植入耗材产品的开发，首款Ⅲ类 器械产品"科凝Colloidose 可吸收止血流体明胶"于2024年10月获得国家药监局批准的医疗器械证。 止血流体明胶产品被广泛用于不可压迫组织创面（脑、脊柱等）和微创手术的止血应用，全球止血流体 市场以强生和百特的流体明胶产品为主流。传统止血流体明胶产品以"明胶微米造粒"技术为主流，其中 强生的多孔造粒技术是微米造粒技术路线的代表。针对此，华诺生物自主研发"自愈合超分子"技术并开 发出全新的流体明胶技术路线，在保持微创注射特性的同时提升流体明胶的力学性能。 国中资本投资团队表示，华诺生物实现了高端止血材料的供应链国产化及生产工艺全流程的自主可控， 未来有望将该技术平台延伸至更多创新性医用耗材的开发与应用。 ...

Core Insights - Shenzhen Huano Biotechnology Co., Ltd. has completed an A+ round of financing led by Guozhong Capital, with funds primarily allocated for expanding its product pipeline based on its self-healing supramolecular technology platform and upgrading the production capacity of core products [1][4] Group 1: Company Overview - Huano Biotechnology innovatively applies "self-healing supramolecular" technology to develop injectable and moldable fluid implant materials, with its first Class III medical device product, "Colloidose® absorbable hemostatic fluid gelatin," expected to receive approval from the National Medical Products Administration in October 2024 [1][3] - The company was founded in December 2017 by a team led by a Harvard University PhD and is recognized as a national high-tech enterprise, boasting over 20 years of experience in the biomaterials industry and having published more than 100 research papers in top academic journals [3] Group 2: Product and Market Position - The hemostatic fluid gelatin product is widely used in non-compressible tissue wounds (such as brain and spine) and minimally invasive surgical hemostasis, with the global market dominated by Johnson & Johnson and Baxter's fluid gelatin products [3] - Huano's self-developed "self-healing supramolecular" technology offers a new route for fluid gelatin, enhancing mechanical properties while maintaining minimally invasive injection characteristics, achieving rapid gel solidification and physical sealing of bleeding points with reduced dosage and faster degradation [3] Group 3: Future Prospects - Guozhong Capital's investment team indicates that Huano Biotechnology has achieved domestic supply chain localization for high-end hemostatic materials and has full control over the production process, suggesting potential for extending this technology platform to develop and apply more innovative medical consumables in the future [4]